▶ 調査レポート

遅発性ジスキネジア治療の世界市場:成長・動向・市場規模予測(2020-2025)

• 英文タイトル:Tardive Dyskinesia Treatment Market - Growth, Trends, and Forecast (2020 - 2025)

Mordor Intelligenceが調査・発行した産業分析レポートです。遅発性ジスキネジア治療の世界市場:成長・動向・市場規模予測(2020-2025) / Tardive Dyskinesia Treatment Market - Growth, Trends, and Forecast (2020 - 2025) / D0-MOR-AP1125資料のイメージです。• レポートコード:D0-MOR-AP1125
• 出版社/出版日:Mordor Intelligence / 2020年4月20日
• レポート形態:英文、PDF、117ページ
• 納品方法:Eメール(受注後2-3営業日)
• 産業分類:健康管理
• 販売価格(消費税別)
  Single User¥484,500 (USD4,250)▷ お問い合わせ
  Team User¥541,500 (USD4,750)▷ お問い合わせ
  Corporate License¥855,000 (USD7,500)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
本調査レポートは、遅発性ジスキネジア治療の世界市場について調査・分析した資料で、遅発性ジスキネジア治療の市場概要、動向、セグメント別市場規模、地域別分析、競争状況、企業情報、市場機会分析などで構成されています。

The Tardive Dyskinesia Treatment Market is expected to register a CAGR of 4% during the forecast period. This is attributing to growing number of Schizophrenia Patients, rising incidences of neurological disorders. With prolonged use of antipsychotic drugs by schizophrenia patients, the chances of patients suffering from tardive dyskinesia are high. Thus high risk associated with growing number of antipsychotic drugs leading to promote the growth of the overall market. Tardive dyskinesia is an involuntary neurological movement disorder wherein there is an uncontrolled movement of body parts such as eyeballs, lips, and tongue. Moreover, the strong clinical trial pipeline for the treatment of tardive dyskinesia by several manufacturing companies is also boosting the market.
However, side effects of drugs lack awareness about the disorder and many undiagnosed cases may restrain the market to a certain extent.

Key Market Trends

VMAT Inhibitor is Expected to Witness a healthy Growth in Future

VMAT is expected to witness healthy growth in the future attributed to a growing number of neurological disorders and growing antipsychotic prescriptions. Several product approvals in VMAT inhibitors are promoting the growth of the market. For instance, in 2017 Neurocine biosciences got approval from the Food and Drug Administration (FDA) for a drug Valbenazine marketed under Ingrezza for the treatment of Tardive dyskinesia. In addition, Teva Pharmaceuticals drug name Austedo also gets approval. This results in driving the Tardive dyskinesia Treatment market.

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

North America is expected to hold a significant market share in the global Tardive Dyskinesia Treatment Market due to the increasing aging population, high prevalence of schizophrenia, increasing awareness, increasing healthcare expenditure and the presence of well-established healthcare infrastructure. As growing aging population will be leading to many diseases related to neurological for which this population has to take antipsychiatric drugs. Thus these populations are more prone to develop these diseases. Moreover, targeted patient pools such as populations treated with schizophrenia and bipolar disorder in this region are also associated with this disorder, hence promotes the growth of the tardive dyskinesia treatment market in this region.

Competitive Landscape

The Tardive Dyskinesia Treatment Market is moderately competitive and consists of several major players. Some of the companies which are currently dominating the market are Teva Pharmaceutical Industries Ltd Neurocrine Biosciences, Inc, Sun Pharmaceutical Industries Ltd, SteriMax Inc., Lannett Co Inc, Sanis, and Allergan

Reasons to Purchase this report:

– The market estimate (ME) sheet in Excel format
– 3 months of analyst support

レポート目次

1 INTRODUCTION
1.1 Study Assumptions
1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Number of Neurological Disorder
4.2.2 Growing Antipsychotic Prescriptions
4.2.3 Rising Schizophrenia Patients
4.3 Market Restraints
4.3.1 Side Effects of Drugs
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION
5.1 By Disorder
5.1.1 Bradykinesias
5.1.2 Hyperkinesias
5.2 By Drug Class
5.2.1 Dopamine-Depleting Medications
5.2.2 VMAT2 Inhibitors
5.2.3 GABA Receptor Agonist Medications
5.2.4 Anticholinergic Medications Trihexyphenidyl
5.3 By End User
5.3.1 Hospitals
5.3.2 Clinical
5.3.3 Others
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle-East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle-East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Teva Pharmaceutical Industries Ltd
6.1.2 Neurocrine Biosciences, Inc
6.1.3 Sun Pharmaceutical Industries Ltd
6.1.4 SteriMax Inc.
6.1.5 Lannett Co Inc
6.1.6 Sanis
6.1.7 Allergan

7 MARKET OPPORTUNITIES AND FUTURE TRENDS